Page 2422 - Williams Hematology ( PDFDrive )

2393
2393
2393

INDEX

Page numbers in bold indicate a major discussion of the topic. Page numbers followed by f and t indicate the location of figures and tables,
respectively.

A mismatch in hematopoietic cell aCML (atypical chronic myelogenous
AA4, 260 transplantation, 2373–2374, 2373t leukemia), 1279
AA amyloidosis, 1773, 1774t phenotypes, 2333t Acquired hemophilia A, 2145, 2183–2186
AAV (adeno-associated viral) vectors, serologic detection, 2348, 2349t Acquired immunodeficiency syndrome. See
438–439, 442, 2129 von Willebrand factor levels and, 2171 AIDS
ABCB7, 918 ABO hemolytic disease, 851, 852t, 856f. Acquired prothrombin complex deficiency,
ABCD1, 439 See also Alloimmune hemolytic 109
Abciximab, 405–406 disease of the fetus and newborn Acquired pure amegakaryocytic
clinical uses, 404t, 405–406, 2077 (HDFN) thrombocytopenia, 1999
dosage, 404t ABO-Rh compatibility guidelines, 2350t Acquired von Willebrand syndrome (AVWS),
mechanism of action, 404t Abortion, spontaneous, 1988, 2239 2082–2083, 2174–2175
for peripheral vascular disease, 2316 Abraxane, 326 Acral cyanosis, 2205t
pseudothrombocytopenia and, Abruptio placentae, 2210 Acrocentric centromere, 175t
1995–1996 Absolute anemia, 506, 507t. See also Anemia Acrocyanosis, 829
thrombocytopenia and, 2077 ABT-199 (venetoclax) ACS (acute coronary syndrome), 2295.
for unstable angina, 2296 for chronic lymphocytic leukemia, 1539 See also Myocardial infarction (MI)
Abdominal pain/fullness for mantle cell lymphoma, 1660t ACTG1, 234t, 1737
in acute intermittent porphyria, 902 ABT-737, 1403 Actin, 663t, 667, 1832t, 1838–1839, 1839f,
in chronic myelogenous leukemia, ABVD regimen, for Hodgkin lymphoma 1840–1841
1445 in advanced disease, 1614 α-Actinin, 1832t
in enteropathy-associated T-cell clinical trials, 1611, 1615t Activated B-cell-like diffuse large B-cell
lymphoma, 1699 complications, 1617–1618 lymphoma, 234–235t, 1495t, 1626,
in follicular lymphoma, 1641 dose, route, and schedule, 1612t 1627t
history of, 5 history, 1604, 1611 Activated partial thromboplastin time
in polycythemia vera, 1293 in HIV-associated disease, 1247–1248 (aPTT)
Abelson oncogene. See ABL1 in limited-stage disease, 1611, 1613 in antiphospholipid syndrome, 2243
Abetalipoproteinemia (Bassen-Kornzweig in nodular lymphocyte-predominant in disseminated intravascular coagulation,
syndrome), 670f, 681 disease, 1616 2205t
Aβ peptide, 1848 with radiation therapy, 1248, 1613, 1614 in hemophilia A, 2120
ABL1. See also BCR-ABL1 in unfavorable limited-stage disease, 1613 in hemostatic disorders, 1988, 1989f
in B-cell acute lymphoblastic leukemia, Acanthocytes, 21f, 472f, 472t, 474f, 475, 671f, in heparin monitoring, 397
232t 680 Activated protein C (APC), 1949–1950,
in chronic myelogenous leukemia, 176, Acanthocytosis, 680–681 1950f, 1954
1438, 1441–1442, 1442f, Accelerated phase, of chronic myelogenous activities, 1954–1955
1456–1457, 1457t leukemia. See Chronic anticoagulant cofactors, 1918t, 1923,
ABL2, 232t myelogenous (myeloid) leukemia 1955–1956, 2202
ABO blood group, 2330 (CML), accelerated phase and blast direct cellular activities, 1923, 1956–1958,
antibodies, 2341t, 2344t, 2350t crisis 1957f
antigens, 2331t, 2337, 2339, 2340, 2350t Accessory spleen, 88 endothelial protein C receptor and, 1953
cardiovascular risk and, 2288 Aceruloplasminemia, 640 inhibition, 1958
characteristics, 2331t, 2333t Acetaminophen, 767, 2375 neuroprotective effects, 1956
compatibility guidelines, 2350t Acetylcholinesterase, 692t, 701t protein S and, 1926
discrepancies, 2349t Acetyl-coenzyme A (CoA), 193, 193f, 196 sepsis and, 1956, 2202
disease association, 2331t, 2341t Acid-sphingomyelinase deficiency. See structure, 1923
frequency, 2333t Niemann-Pick disease therapeutic forms, 1952
Fy(a–b–) phenotype, 2339 Aclarubicin, for acute myelogenous leukemia, Activated protein C (APC) concentrate,
genetics, 2339 1395 2213

Kaushansky_index_p2393-2506.indd 2393 9/21/15 3:21 PM